Evidence map›Paper›PMID 28058627›Full record

ArticleMedical oncology (Northwood, London, England)2017

A surface tension magnetophoretic device for rare cell isolation and characterization.

Emma E van der Toom, James E Verdone, Changhan Jun, Doru Petrisor, Sunghwan Lim, Jean J M C H de la Rosette, Theo M de Reijke, Michael A Gorin, Kenneth J Pienta, Dan Stoianovici

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Emma E van der ToomDepartment of Urology, The James Buchanan Brady Urological Institute, School of Medicine, Johns Hopkins University, Baltimore, MD, 21287, USA.
James E VerdoneDepartment of Urology, The James Buchanan Brady Urological Institute, School of Medicine, Johns Hopkins University, Baltimore, MD, 21287, USA.
Changhan JunDepartment of Urology, The James Buchanan Brady Urological Institute, School of Medicine, Johns Hopkins University, Baltimore, MD, 21287, USA.
Doru PetrisorDepartment of Urology, The James Buchanan Brady Urological Institute, School of Medicine, Johns Hopkins University, Baltimore, MD, 21287, USA.
Sunghwan LimDepartment of Urology, The James Buchanan Brady Urological Institute, School of Medicine, Johns Hopkins University, Baltimore, MD, 21287, USA.
Jean J M C H de la RosetteDepartment of Urology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Theo M de ReijkeDepartment of Urology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Michael A GorinDepartment of Urology, The James Buchanan Brady Urological Institute, School of Medicine, Johns Hopkins University, Baltimore, MD, 21287, USA.
Kenneth J PientaDepartment of Urology, The James Buchanan Brady Urological Institute, School of Medicine, Johns Hopkins University, Baltimore, MD, 21287, USA.
Dan StoianoviciDepartment of Urology, The James Buchanan Brady Urological Institute, School of Medicine, Johns Hopkins University, Baltimore, MD, 21287, USA. dss@jhu.edu.ORCID http://orcid.org/0000-0001-6635-9647

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Tumor microvesicle-mediated modulation of the bone microenvironmentP01CA093900 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PIENTA, KENNETH J. · 2004 to 2024
$29.6M
TRANS_NETWORK PROJECTSU54CA143803 · NCI · PRINCETON UNIVERSITY · PI GETZENBERG, ROBERT H. · 2009 to 2013
$14.2M
Mechanisms That Regulate Dormancy of Disseminated Tumor Cells in the Bone MarrowU54CA163124 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHIOZAWA, YUSUKE · 2011 to 2015
$3.0M
Reactive Stroma and Tumor Associated Macrophages in Prostate Cancer ProgressionU01CA143055 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PIENTA, KENNETH J., ROWLEY, DAVID R · 2010 to 2014
$2.7M
NCI NIH HHS P01 CA093900NCI NIH HHS P30 CA006973NCI NIH HHS U01 CA143055NCI NIH HHS U54 CA143803NCI NIH HHS U54 CA163124
6 · The paper itself

Abstract

The cancer community continues to search for an efficient and cost-effective technique to isolate and characterize circulating cells (CTCs) as a 'real-time liquid biopsy'. Existing methods to isolate and analyze CTCs require various transfer, wash, and staining steps that can be time consuming, expensive, and led to the loss of rare cells. To overcome the limitations of existing CTC isolation strategies, we have developed an inexpensive 'lab on a chip' device for the enrichment, staining, and analysis of rare cell populations. This device utilizes immunomagnetic positive selection of antibody-bound cells, isolation of cells through an immiscible interface, and filtration. The isolated cells can then be stained utilizing immunofluorescence or used for other downstream detection methods. We describe the construction and initial preclinical testing of the device. Initial tests suggest that the device may be well suited for the isolation of CTCs and could allow the monitoring of cancer progression and the response to therapy over time.

Indexed as

Cell Line, TumorHumansImmunomagnetic SeparationLab-On-A-Chip DevicesMaleNeoplastic Cells, CirculatingProstatic NeoplasmsSurface PropertiesCirculating tumor cellsMagnetophoresisMicro-fluidic deviceProstate cancerRare cells

Identifiers

PMID28058627
PMCPMC5801755

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.